Invesco Ltd. Supernus Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

$557 Billion
Q2 2025

A detailed history of Invesco Ltd. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 399,019 shares of SUPN stock, worth $16.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

399,019

Previous 530,631 24.8%

Holding current value

$16.5 Million

Previous $17.4 Million 27.63%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$30.29 - $33.43 $3.99 Million - $4.4 Million	-131,612 Reduced 24.8%	399,019 $12.6 Million
Q1 2025 May 12, 2025	BUY	$31.17 - $40.0 $703,257 - $902,480	22,562 Added 4.44%	530,631 $17.4 Million
Q4 2024 Feb 13, 2025	BUY	$31.89 - $37.83 $702,441 - $833,281	22,027 Added 4.53%	508,069 $18.4 Million
Q3 2024 Nov 12, 2024	SELL	$25.77 - $35.16 $2.65 Million - $3.61 Million	-102,661 Reduced 17.44%	486,042 $15.2 Million
Q2 2024 Aug 13, 2024	SELL	$25.99 - $33.85 $391,695 - $510,153	-15,071 Reduced 2.5%	588,703 $15.7 Million
Q1 2024 May 14, 2024	BUY	$27.11 - $35.17 $2 Million - $2.6 Million	73,826 Added 13.93%	603,774 $20.6 Million
Q4 2023 Feb 12, 2024	SELL	$22.72 - $29.68 $3.47 Million - $4.53 Million	-152,743 Reduced 22.37%	529,948 $15.3 Million
Q3 2023 Nov 13, 2023	SELL	$27.57 - $32.91 $1.79 Million - $2.13 Million	-64,791 Reduced 8.67%	682,691 $18.8 Million
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $2.02 Million - $2.62 Million	67,669 Added 9.95%	747,482 $22.5 Million
Q1 2023 May 12, 2023	BUY	$34.93 - $42.03 $922,955 - $1.11 Million	26,423 Added 4.04%	679,813 $24.6 Million
Q4 2022 Feb 13, 2023	BUY	$31.09 - $37.88 $589,497 - $718,242	18,961 Added 2.99%	653,390 $23.3 Million
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $1.38 Million - $1.7 Million	-47,887 Reduced 7.02%	634,429 $21.5 Million
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $1.56 Million - $2.11 Million	61,537 Added 9.91%	682,316 $19.7 Million
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $3.52 Million - $4.06 Million	-123,486 Reduced 16.59%	620,779 $20.1 Million
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $7.58 Million - $9.84 Million	-287,515 Reduced 27.87%	744,265 $21.7 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $6.44 Million - $8.58 Million	273,377 Added 36.05%	1,031,780 $27.5 Million
Q2 2021 Aug 17, 2021	BUY	$26.72 - $33.19 $831,526 - $1.03 Million	31,120 Added 4.28%	758,403 $23.4 Million
Q1 2021 May 17, 2021	SELL	$24.15 - $31.45 $1.76 Million - $2.3 Million	-73,055 Reduced 9.13%	727,283 $19 Million
Q4 2020 Feb 16, 2021	BUY	$17.7 - $25.81 $1.15 Million - $1.68 Million	64,970 Added 8.84%	800,338 $20.1 Million
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $712,151 - $883,137	35,255 Added 5.04%	735,368 $15.3 Million
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $1.97 Million - $2.87 Million	-115,278 Reduced 14.14%	700,113 $16.6 Million
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $3.19 Million - $5.45 Million	-220,544 Reduced 21.29%	815,391 $14.7 Million
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $13.8 Million - $20.1 Million	690,310 Added 199.73%	1,035,935 $24.6 Million
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $1.36 Million - $1.79 Million	-53,546 Reduced 13.41%	345,625 $9.5 Million
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $14.4 Million - $18.6 Million	-479,378 Reduced 54.56%	399,171 $13.2 Million
Q1 2019 May 15, 2019	SELL	$32.77 - $41.99 $1.64 Million - $2.1 Million	-50,075 Reduced 5.39%	878,549 $30.8 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $28.6 Million - $46 Million	928,624 New	928,624 $30.8 Million

Others Institutions Holding SUPN

# of Institutions

311

Shares Held

61.6M

Call Options Held

18.4K

Put Options Held

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.21B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account